focus -WSS

focus

author：focus 2025-10-01 12:54:42 - browse：333

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Judge orders hearing on Trump's motion to disqualify Fulton County DA

WSS

Texas Department of Public Safety speaks out on migrant abuse allegations

Driven by the pandemic, applicants flood public health schools

Doctors increasingly discourage vaping amid mounting health concerns

Ending racial health disparities hinges on penalties, political will

5 wounded, 2 critically, in Michigan shopping center shooting

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

focus

focus

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Mass General totes up its waste in a move to tackle climate change

Moonlake's readout produced a cash windfall. Risks remain

Teacher posts viral 'school supply rant' with advice for parents

Guidelines to prevent youth baseball injuries need more muscle

What AstraZeneca

After affirmative action ruling, medical educators look to 'holistic review'

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Psychedelics group wrestles with new pharma identity

Study identifies new proteins linked to dementia risk 25 years later

focus

Awakening the world to the whoosh: A patient's crusade

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Judge rejects Trump's request to move Stormy Daniels hush

Doctors increasingly discourage vaping amid mounting health concerns

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Driven by the pandemic, applicants flood public health schools

explore

hotspot

entertainment

Wikipedia